403 related articles for article (PubMed ID: 16218172)
1. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.
Sheldon J; Camino N; Rodés B; Bartholomeusz A; Kuiper M; Tacke F; Núñez M; Mauss S; Lutz T; Klausen G; Locarnini S; Soriano V
Antivir Ther; 2005; 10(6):727-34. PubMed ID: 16218172
[TBL] [Abstract][Full Text] [Related]
2. Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.
Audsley J; Arrifin N; Yuen LK; Ayres A; Crowe SM; Bartholomeusz A; Locarnini SA; Mijch A; Lewin SR; Sasadeusz J
HIV Med; 2009 Apr; 10(4):229-35. PubMed ID: 19178592
[TBL] [Abstract][Full Text] [Related]
3. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
Quiros-Roldan E; Calabresi A; Lapadula G; Tirelli V; Costarelli S; Cologni G; Zaltron S; Puoti M; Carosi G; Torti C
Antivir Ther; 2008; 13(3):341-8. PubMed ID: 18572746
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort.
Alvarez-Uria G; Ratcliffe L; Vilar J
HIV Med; 2009 May; 10(5):269-73. PubMed ID: 19210695
[TBL] [Abstract][Full Text] [Related]
5. High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B.
Mendes-Correa MC; Pinho JR; Locarnini S; Yuen L; Sitnik R; Santana RA; Gomes-Gouvêa MS; Leite OM; Martins LG; Silva MH; Gianini RJ; Uip DE
J Med Virol; 2010 Sep; 82(9):1481-8. PubMed ID: 20648600
[TBL] [Abstract][Full Text] [Related]
6. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.
Benhamou Y; Fleury H; Trimoulet P; Pellegrin I; Urbinelli R; Katlama C; Rozenbaum W; Le Teuff G; Trylesinski A; Piketty C;
Hepatology; 2006 Mar; 43(3):548-55. PubMed ID: 16496322
[TBL] [Abstract][Full Text] [Related]
7. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
8. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains.
Amini-Bavil-Olyaee S; Herbers U; Sheldon J; Luedde T; Trautwein C; Tacke F
Hepatology; 2009 Apr; 49(4):1158-65. PubMed ID: 19263474
[TBL] [Abstract][Full Text] [Related]
9. The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations.
Zhu Y; Curtis M; Borroto-Esoda K
Antivir Chem Chemother; 2011 Aug; 22(1):13-22. PubMed ID: 21860069
[TBL] [Abstract][Full Text] [Related]
10. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response.
Jain MK; Comanor L; White C; Kipnis P; Elkin C; Leung K; Ocampo A; Attar N; Keiser P; Lee WM
J Viral Hepat; 2007 Mar; 14(3):176-82. PubMed ID: 17305883
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.
Dore GJ; Cooper DA; Pozniak AL; DeJesus E; Zhong L; Miller MD; Lu B; Cheng AK; ;
J Infect Dis; 2004 Apr; 189(7):1185-92. PubMed ID: 15031786
[TBL] [Abstract][Full Text] [Related]
12. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
Stephan C; Berger A; Carlebach A; Lutz T; Bickel M; Klauke S; Staszewski S; Stuermer M
J Antimicrob Chemother; 2005 Dec; 56(6):1087-93. PubMed ID: 16269552
[TBL] [Abstract][Full Text] [Related]
13. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
Schmutz G; Nelson M; Lutz T; Sheldon J; Bruno R; von Boemmel F; Hoffmann C; Rockstroh J; Stoehr A; Wolf E; Soriano V; Berger F; Berg T; Carlebach A; Schwarze-Zander C; Schürmann D; Jaeger H; Mauss S
AIDS; 2006 Oct; 20(15):1951-4. PubMed ID: 16988516
[TBL] [Abstract][Full Text] [Related]
14. Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient.
Amini-Bavil-Olyaee S; Sheldon J; Lutz T; Trautwein C; Tacke F
AIDS; 2009 Jan; 23(2):268-72. PubMed ID: 19098499
[TBL] [Abstract][Full Text] [Related]
15. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.
van Bömmel F; Zöllner B; Sarrazin C; Spengler U; Hüppe D; Möller B; Feucht HH; Wiedenmann B; Berg T
Hepatology; 2006 Aug; 44(2):318-25. PubMed ID: 16871563
[TBL] [Abstract][Full Text] [Related]
16. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
Masquelier B; Neau D; Boucher S; Lavignolle-Aurillac V; Schrive MH; Recordon-Pinson P; Ragnaud JM; Fleury H
Antivir Ther; 2006; 11(6):827-30. PubMed ID: 17310827
[TBL] [Abstract][Full Text] [Related]
17. Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir.
Matthews GV; Cooper DA; Dore GJ
Antivir Ther; 2007; 12(1):119-22. PubMed ID: 17503756
[TBL] [Abstract][Full Text] [Related]
18. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants.
van der Eijk AA; Hansen BE; Niesters HG; Janssen HL; van de Ende M; Schalm SW; de Man RA
J Viral Hepat; 2005 Jul; 12(4):364-72. PubMed ID: 15985006
[TBL] [Abstract][Full Text] [Related]
19. Detection of hepatitis B virus variants in HBV monoinfected and HBV/HIV coinfected Iranian patients under lamivudine treatment.
Aghasadeghi MR; Bahramali G; Sadat SM; Farahani A; Mohraz M; Davar Siadat S; Mostafavi E; Memarnejadian A; Ardestani MS; Vahabpour R; Saraji AA; Delbaz SA
Curr HIV Res; 2011 Jun; 9(4):263-9. PubMed ID: 21671883
[TBL] [Abstract][Full Text] [Related]
20. Wild type and YMDD variant of hepatitis B virus: no difference in viral kinetics on lamivudine/tenofovir therapy in HIV-HBV co-infected patients.
de Vries-Sluijs TE; van der Eijk AA; Hansen BE; Osterhaus AD; de Man RA; van der Ende ME
J Clin Virol; 2006 May; 36(1):60-3. PubMed ID: 16418013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
